Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M65T | ISIN: SE0002148817 | Ticker-Symbol: 24H
Frankfurt
06.06.25 | 08:01
2,108 Euro
-1,86 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HANSA BIOPHARMA AB Chart 1 Jahr
5-Tage-Chart
HANSA BIOPHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,1042,30616:56

Aktuelle News zur HANSA BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Hansa Biopharma Plans Restructuring2
26.05.Hansa Biopharma AB: Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency179Lund, Sweden, 26 May 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that it plans to restructure the organization to optimize resource allocation and improve operational...
► Artikel lesen
26.05.Notice to Annual General Meeting in Hansa Biopharma AB (publ)1
14.05.Hansa Biopharma AB: Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS246LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first...
► Artikel lesen
13.05.Hansa Biopharma Taps Maria Törnsén as COO and President U.S.2
13.05.Hansa Biopharma AB: Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.240LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President...
► Artikel lesen
24.04.Hansa Biopharma Q1 2025 slides: 39% sales growth amid expanding EU commercialization3
24.04.Hansa Biopharma Appoints New CEO1
HANSA BIOPHARMA Aktie jetzt für 0€ handeln
24.04.Hansa Biopharma reports Q1 results3
24.04.Hansa Biopharma AB: Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results262Strong product sales and key progress in pipeline catalysts LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today...
► Artikel lesen
24.04.Hansa Biopharma AB: Hansa Biopharma appoints new Chief Executive Officer155Lund, Sweden, 24 April 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren...
► Artikel lesen
03.04.HANSA BIOPHARMA AB: Hansa Biopharma to host Q1 2025 interim results conference call4
25.03.HANSA BIOPHARMA AB: Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference3
21.03.Hansa Biopharma AB: Hansa Biopharma publishes 2024 Annual and Sustainability Reports312LUND, Sweden, March 21, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024. Peter...
► Artikel lesen
11.03.Hansa Biopharma AB: Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients274LUND, Sweden, March 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization...
► Artikel lesen
04.03.HANSA BIOPHARMA AB: Hansa Biopharma to attend Leerink Partners Global Healthcare Conference1
24.02.HANSA BIOPHARMA AB: Hansa Biopharma to attend TD Cowen Healthcare Conference1
06.02.Hansa Biopharma reports Q4 results3
06.02.Hansa Biopharma sees 2025 growth through expanded IDEFIRIX adoption and new market reimbursements2
06.02.Hansa Biopharma AB: Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results345IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1